<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00969865</url>
  </required_header>
  <id_info>
    <org_study_id>iCARE</org_study_id>
    <nct_id>NCT00969865</nct_id>
  </id_info>
  <brief_title>Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program</brief_title>
  <acronym>iCARE</acronym>
  <official_title>Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Piedmont Healthcare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Piedmont Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of an individualized approach to diagnosing and/or&#xD;
      treating atherosclerosis. This will be done by combining genetic information, lifestyle&#xD;
      information, participant education, and imaging tests to track diagnoses, therapies, and&#xD;
      treatment on two groups: 1) Standard Management Group (diagnosed and/or treated according to&#xD;
      standard of care) and 2) Individualized Management Group (standard of care plus genetic&#xD;
      testing and coronary artery calcium scans).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this proposal is to create a large, community-based demonstration project to&#xD;
      evaluate the value of a highly individualized approach to atherosclerosis risk reduction. In&#xD;
      this project we set out to compare the delivery of appropriate therapies and resource&#xD;
      utilization using current national guidelines for the management of atherosclerosis and will&#xD;
      compare this to using a highly individualized approach for atherosclerosis risk reduction,&#xD;
      based on the evaluation of specific features in individuals and tailoring management based on&#xD;
      this evaluation. We plan to show that utilizing the iCARE Program, more patients will receive&#xD;
      appropriate diagnoses and subsequent therapies in a more efficient manner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the proportion of subjects and patients who are diagnosed with subclinical and clinically significant coronary atherosclerosis with the PHI-ACE-iCARE approach, compared to the current guideline-driven approach.</measure>
    <time_frame>6 months, 12 months, 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the proportion of patients who receive appropriate revascularization procedures for clinically significant coronary atherosclerosis with the PHI-ACE-iCARE approach, compared to the current guideline-driven approach.</measure>
    <time_frame>6 month, 12 months, 18 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">170</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Individualized Managment Group</arm_group_label>
    <description>Participants receiving, in addition to standard of care, blood tests for markers of heart disease, DNA and RNA analysis, and coronary artery calcium scan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Management Group</arm_group_label>
    <description>Participants who receive standard of care.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with no known coronary artery disease and who have an intermediate or high&#xD;
        Framingham Risk Score (10 year risk 10 percent or greater).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No known coronary artery disease&#xD;
&#xD;
               -  no prior coronary disease by cardiac catheterization (â‰¤39% in any major&#xD;
                  epicardial vessel)&#xD;
&#xD;
               -  no prior myocardial infarction&#xD;
&#xD;
               -  no prior ST-elevation myocardial infarction (1 mm ST-elevation in 2 contiguous&#xD;
                  leads)&#xD;
&#xD;
               -  no prior non-ST-elevation myocardial infarction (CK-MB &gt; 2x ULN or elevated&#xD;
                  troponin that is indicative of myocardial necrosis based on local institutional&#xD;
                  cutpoints)&#xD;
&#xD;
               -  no prior coronary revascularization procedure&#xD;
&#xD;
          -  Intermediate or high Framingham Risk Score (10-year risk 10% or greater)&#xD;
&#xD;
          -  Ability and willingness to provide consent and Authorization for use of PHI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of known cardiomyopathy&#xD;
&#xD;
          -  Presence of permanent pacemaker, defibrillator, or CRT device&#xD;
&#xD;
          -  Presence of clinically significant, uncontrolled arrhythmia (chronic or paroxysmal&#xD;
             atrial fibrillation is NOT an exclusion. Arrhythmias treated successfully with&#xD;
             ablation are not an exclusion.&#xD;
&#xD;
          -  Presence of a known genetic abnormality of cholesterol metabolism (e.g. familial&#xD;
             hypercholesterolemia)&#xD;
&#xD;
          -  Inability or unwillingness to adhere to follow up schedule&#xD;
&#xD;
          -  Inability or unwillingness to provide informed consent and Authorization for use of&#xD;
             PHI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piedmont Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Piedmont Heart Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>August 31, 2009</study_first_submitted>
  <study_first_submitted_qc>August 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2009</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

